CL2022002562A1 - Nuevos análogos de il-2 inmunoestimuladores - Google Patents

Nuevos análogos de il-2 inmunoestimuladores

Info

Publication number
CL2022002562A1
CL2022002562A1 CL2022002562A CL2022002562A CL2022002562A1 CL 2022002562 A1 CL2022002562 A1 CL 2022002562A1 CL 2022002562 A CL2022002562 A CL 2022002562A CL 2022002562 A CL2022002562 A CL 2022002562A CL 2022002562 A1 CL2022002562 A1 CL 2022002562A1
Authority
CL
Chile
Prior art keywords
analogues
interleukin
novel immunostimulatory
immunostimulatory
novel
Prior art date
Application number
CL2022002562A
Other languages
English (en)
Spanish (es)
Inventor
Lim Oh Euh
Yun Kim Sang
Ho Heo Yong
Young Kim Jin
Rong Park Cho
Sub Park Jun
soo ryu Hyun
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2022002562A1 publication Critical patent/CL2022002562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2022002562A 2020-03-31 2022-09-21 Nuevos análogos de il-2 inmunoestimuladores CL2022002562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200039476 2020-03-31

Publications (1)

Publication Number Publication Date
CL2022002562A1 true CL2022002562A1 (es) 2023-03-17

Family

ID=77930406

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002562A CL2022002562A1 (es) 2020-03-31 2022-09-21 Nuevos análogos de il-2 inmunoestimuladores
CL2026001105A CL2026001105A1 (es) 2020-03-31 2026-04-07 Nuevos análogos de il-2 inmunoestimuladores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2026001105A CL2026001105A1 (es) 2020-03-31 2026-04-07 Nuevos análogos de il-2 inmunoestimuladores.

Country Status (17)

Country Link
US (2) US11746137B2 (cg-RX-API-DMAC7.html)
EP (1) EP4130027A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846627B2 (cg-RX-API-DMAC7.html)
KR (2) KR102545250B1 (cg-RX-API-DMAC7.html)
CN (2) CN115427437B (cg-RX-API-DMAC7.html)
AR (1) AR121713A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021202825B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022018730A2 (cg-RX-API-DMAC7.html)
CA (2) CA3266069A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002562A1 (cg-RX-API-DMAC7.html)
IL (1) IL295826B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011893A (cg-RX-API-DMAC7.html)
NZ (1) NZ793819A (cg-RX-API-DMAC7.html)
PE (1) PE20221759A1 (cg-RX-API-DMAC7.html)
TW (1) TWI876021B (cg-RX-API-DMAC7.html)
WO (1) WO2021201615A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202209565B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121713A1 (es) * 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
KR20250126198A (ko) 2024-02-15 2025-08-25 한림대학교 산학협력단 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285989A (en) * 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
AU627477B2 (en) * 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
CA2019714A1 (en) 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2007201663A1 (en) 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
KR20140106452A (ko) 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
CN107148279B (zh) 2014-10-21 2021-09-03 赛生药品股份国际有限公司 用免疫刺激剂治疗癌症
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR20160134989A (ko) 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN107266553A (zh) * 2016-04-08 2017-10-20 南京康志制药有限公司 高效人白细胞介素ⅱ突变体融合蛋白及其应用
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN110913954A (zh) * 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
JP7356726B2 (ja) * 2017-09-25 2023-10-05 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
US10946068B2 (en) * 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7534215B2 (ja) * 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
MX2020012251A (es) * 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
SG11202005873QA (en) * 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
US20220025007A1 (en) * 2018-12-21 2022-01-27 Hanmi Pharm. Co., Ltd. Novel immunosuppressive interleukin 2
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114437198A (zh) 2019-12-17 2022-05-06 北京志道生物科技有限公司 白介素-2衍生物
BR112022017656A2 (pt) 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
AR121713A1 (es) * 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes

Also Published As

Publication number Publication date
NZ793819A (en) 2026-03-27
US11746137B2 (en) 2023-09-05
CA3169564C (en) 2025-05-06
TW202204387A (zh) 2022-02-01
CL2026001105A1 (es) 2026-05-15
KR20230088656A (ko) 2023-06-20
CN118271419A (zh) 2024-07-02
WO2021201615A1 (ko) 2021-10-07
KR102946368B1 (ko) 2026-04-01
EP4130027A1 (en) 2023-02-08
KR102545250B1 (ko) 2023-06-21
US20230348550A1 (en) 2023-11-02
JP7846627B2 (ja) 2026-04-15
AU2021202825B2 (en) 2022-06-30
PE20221759A1 (es) 2022-11-11
IL295826A (en) 2022-10-01
JP2023515247A (ja) 2023-04-12
ZA202209565B (en) 2023-12-20
IL295826B2 (en) 2025-11-01
CA3169564A1 (en) 2021-10-07
EP4130027A4 (en) 2024-08-14
IL295826B1 (en) 2025-07-01
BR112022018730A2 (pt) 2022-11-01
US20230124171A1 (en) 2023-04-20
AU2022203841A1 (en) 2022-06-23
JP2024041747A (ja) 2024-03-27
KR20210122200A (ko) 2021-10-08
AR121713A1 (es) 2022-06-29
CA3266069A1 (en) 2026-03-02
TWI876021B (zh) 2025-03-11
CN115427437A (zh) 2022-12-02
MX2022011893A (es) 2022-10-18
AU2021202825A1 (en) 2021-10-14
CN115427437B (zh) 2024-04-19
US12415842B2 (en) 2025-09-16

Similar Documents

Publication Publication Date Title
PE20221759A1 (es) Nuevos analogos de il-2 inmunoestimuladores
AR114445A1 (es) Conjugados de il-15, y sus usos
CL2023002504A1 (es) Novedoso conjugado de análogo de il-2 inmunoestimulante y procedimiento de preparación del mismo
MX2022003301A (es) Derivado de interleucina-2.
ECSP21056325A (es) Compuesto heterocíclico y su uso
CO2022000281A2 (es) Receptores de linfocitos t de mage-a4 y métodos de uso de estos
EP4013777A4 (en) MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
CO2018011972A2 (es) Receptores de células t
BR112019022321A2 (pt) Tcr e peptídeos
CL2025002714A1 (es) Receptor de linfocitos t con especificidad para prame presentado en hla-a2; composición farmacéutica; y uso.
BRPI0417184A (pt) dispositvo tipo grampo de sujeição
MX2021015153A (es) Composicion farmaceutica parenteral de agonista dual de glp1/2.
CO2025017638A2 (es) Agonistas espiromacrocíclicos de receptores de orexina 2
PT4021929T (pt) Análogos de ham15-52 com potência melhorada de recetor de amilina (hamy3r)
MX2022012624A (es) Composicion de poliamida para elementos opticos.
JOP20250091A1 (ar) منبهات مستقبلات السوماتوستاتين 2 واستخداماتها
MX2021007548A (es) Adc con enlazadores multiplex de tiol.
MX2025010396A (es) Anticuerpos anti-receptor 3 del factor de crecimiento epidermico humano (her3)/ glicoproteina transmembrana mucina 1 (muc1) y usos de los mismos
EP3947566A4 (en) SILICONE ELASTOMER COMPOSITIONS AND ELASTOMER MATERIALS
UY37651A (es) Polipéptido de unión al il-1r-i
CL2021002407A1 (es) Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias
BR112013029046A2 (pt) composição de moldagem termoplástica, uso de uma composição de moldagem termoplástica, e, fibra, folha, ou peça moldada
MX2024002214A (es) Farmaco de combinacion.
TWD207174S (zh) 刮痧按摩器(一)
BR112021014303A2 (pt) Películas para uso como entrefolhas entre substratos